Ottawa Heart Institute Research Corporation

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cardiac Sarcoidosis Response To Steroids Trial

Phase 4

Withdrawn

Conditions: Cardiac Sarcoidosis
Sarcoidosis

Interventions: Drug: Prednisone

First Posted Date: 2010-09-28

Last Posted Date: 2013-10-30

Lead Sponsor: Ottawa Heart Institute Research Corporation

Registration Number: NCT01210677

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation

Phase 2

Completed

Conditions: Stable Coronary Artery Disease
Acute Coronary Syndrome
Percutaneous Coronary Intervention

Interventions: Genetic: Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers

First Posted Date: 2010-08-18

Last Posted Date: 2011-11-11

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 200

Registration Number: NCT01184300

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Using Automated Calls To Improve Compliance With Acute Coronary Syndrome Best Practice Guidelines

Not Applicable

Completed

Conditions: Acute Coronary Syndrome
Medication Adherence

Interventions: Other: Using IVR to maintain ACS patients on best practice guidelines

First Posted Date: 2010-06-28

Last Posted Date: 2010-06-28

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 1608

Registration Number: NCT01151800

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Rubidium-82 - An Alternative Radiopharmaceutical for Myocardial Imaging(Rb-ARMI)

Completed

Conditions: Coronary Artery Disease

Interventions: Other: Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT

First Posted Date: 2010-05-21

Last Posted Date: 2019-11-21

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 10000

Registration Number: NCT01128023

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Efficacy and Cost-Effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease

Phase 4

Completed

Conditions: Smoking Cessation
Cerebrovascular Disorders

Interventions: Other: Prescription Only Group
Drug: Cost-Free Pharmacotherapy Group

First Posted Date: 2009-08-20

Last Posted Date: 2022-03-10

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 194

Registration Number: NCT00962988

Locations: 🇨🇦
Hamilton Health Sciences -Stroke Prevention Clinic, Hamilton, Ontario, Canada
🇨🇦
The Ottawa Hospital - Stroke Prevention Clinic, Ottawa, Ontario, Canada

Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease

Phase 4

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: Transdermal Nicotine Patch
Drug: Varenicline

First Posted Date: 2009-08-17

Last Posted Date: 2011-04-29

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 50

Registration Number: NCT00959972

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty

Phase 2

Completed

Conditions: Platelet Reactivity

Interventions: Drug: Clopidogrel

First Posted Date: 2009-01-22

Last Posted Date: 2011-04-29

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 100

Registration Number: NCT00827346

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial

Phase 4

Terminated

Conditions: Hematoma

Interventions: Drug: Warfarin or coumadin
Drug: low molecular weight heparin or unfractionated heparin

First Posted Date: 2008-12-01

Last Posted Date: 2018-08-15

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 984

Registration Number: NCT00800137

Locations: 🇨🇦
Sherbrooke University Hospital Centre CHUS, Sherbrooke, Quebec, Canada
🇨🇦
Royal Jubilee Hospital, Victoria, British Columbia, Canada
🇨🇦
Hamilton Health Science Center, Hamilton, Ontario, Canada

and more 19 locations

Cardiac FDG PET Viability Registry

Completed

Conditions: Ischemic Heart Disease
Myocardial Dysfunction
Heart Failure

First Posted Date: 2008-10-06

Last Posted Date: 2024-05-08

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 2000

Registration Number: NCT00766987

Locations: 🇨🇦
London Health Sciences Centre, London, Ontario, Canada
🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

and more 1 locations

CPAP Therapy in Patients With Heart Failure and Obstructive Sleep Apnea.

Phase 1

Completed

Conditions: Obstructive Sleep Apnea
Heart Failure

Interventions: Other: Positron Emission Tomography

First Posted Date: 2008-09-22

Last Posted Date: 2018-05-30

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 67

Registration Number: NCT00756366

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy